Long term subcutaneous administration significantly reduced DUX4 in several muscles of forelimb and hindlimb, reduced muscle pathology, and improved muscle function in FLExDUX4 and ACTA1-MCM;FLExDUX4 FSHD mice. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.